Sharemaestro Newsreel

Fortress Biotech: Q2 Earnings Snapshot

BioAtla (BCAB) turns Q2 2026 profit as cash falls and going concern risk emerges

Instil Bio expects $69.9M cash to fund plan beyond 2027

Damora Therapeutics (DMRA) director awarded 30,350 stock options at $31.00 strike

Damora Therapeutics director Andrew Cheng was granted 30,350 stock options on August 12, 2026, with an exercise price of $31.00 per share and an expiration date of August 12, 2036. These options will vest in equal monthly installments through August 12, 2029, contingent on …

Vivani Medical: Q2 Earnings Snapshot

Damora Therapeutics (DMRA) files Form 3 for new director Andrew Cheng

Damora Therapeutics (DMRA) has filed a Form 3, an initial statement of beneficial ownership, for Andrew Cheng, identifying him as a new director. This filing officially establishes Cheng as a reporting person with the SEC, though it reports no stock transactions at this time. …

Hyperion DeFi Posts Record Q2 Earnings, Expands DeFi Focus

Atrium Therapeutics (RNA) grows collaboration revenue to $22.6M while scaling R&D spend

Is Kyntra Bio Inc (KYNB) Facing Challenges After Q2 Earnings Mis

4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," …

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Regeneron Pharmaceuticals Inc. (REGN) saw its stock price rally by 1.00% to $805.97, outperforming its competitors and the broader market on a strong trading day. This marked the stock's second consecutive day of gains, with the S&P 500 Index and Dow Jones Industrial Average …

Gossamer Bio earnings beat by $0.04, revenue topped estimates

Rani Therapeutics Holdings earnings beat by $0.01, revenue topped estimates

Maze Therapeutics adds two directors to board By Investing.com

Maze Therapeutics, Inc. has announced the appointments of Dr. Paula Johnson and Dr. Sophie Kornowski to its Board of Directors. Dr. Johnson brings extensive experience in cardiology and leadership from Wellesley College and Johnson & Johnson, while Dr. Kornowski contributes over 35 years of …

Maze Therapeutics Announces Appointments to Its Board of Directors

Maze Therapeutics, a clinical-stage biopharmaceutical company, has appointed Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., to its Board of Directors. These appointments bring extensive clinical, research, and biopharmaceutical leadership experience to the company. Maze Therapeutics is advancing its pipeline of small molecule …

Invivyd (IVVD) widens loss, warns on going concern as cash falls to $160M

Invivyd, Inc. (IVVD) reported a widened net loss of $85.8 million for the first half of 2026 and warned of substantial doubt about its ability to continue as a going concern, as its cash and cash equivalents fell to $160.1 million. The company's PEMGARDA …

Invivyd, Inc. Q2 2026: Revenue $14.29M, EPS $(0.14) — 10-Q Summary

Invivyd, Inc. reported its second-quarter 2026 results, showing a 21.2% year-over-year revenue increase to $14.29 million, driven by demand for PEMGARDA. Despite this, the company experienced a widened net loss of $(44.39) million, resulting in a diluted loss per share of $(0.14). Significant progress …

MacroGenics Q2 EPS $(0.31) misses estimate; revenue falls short

MacroGenics (NASDAQ: MGNX) reported a Q2 2026 adjusted EPS of $(0.27), significantly missing the $(0.13) estimate, and revenue of $32.832 million, falling short of the $67.456 million forecast despite a 47.62% YoY increase. The company posted a net income of $19.5 million, a turnaround …

MacroGenics : Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position Announced sale of manufacturing operations ( July 2026) for $122.5 million and transition to fully outsourced model with leaner

MacroGenics reported its second quarter 2026 financial results, highlighting a significant corporate restructuring including the sale of its manufacturing operations for $122.5 million. This transition to a fully outsourced model has streamlined the company, reducing its workforce to approximately 140 people to focus on …

Rocket Pharmaceuticals (RCKT) COO sells 36,658 shares to cover RSU tax withholding

Rocket Pharmaceuticals (RCKT) Chief Operating Officer Christopher James Stevens sold 36,658 shares of common stock at $3.499 per share on August 11, 2026. This sale was conducted to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs). Following the transaction, …

RYTM (NASDAQ: RYTM) investor plans sale of 5,079 shares worth $597K

An investor in Rhythm Pharmaceuticals (NASDAQ: RYTM) has filed a notice to sell 5,079 shares of common stock, valued at $597,290.40. The sale is planned through Morgan Stanley Smith Barney LLC on or after August 13, 2026, on NASDAQ. These shares originate from stock …

Form 8K Inhibrx Biosciences Inc For: 13 August By Investing.com

This article reports on the filing of a Form 8K by Inhibrx Biosciences Inc. for August 13. The brief notice highlights the company's regulatory submission without providing further details on its content. It includes the stock symbol INBX, which saw a slight decrease.

Lexeo Therapeutics (LXEO): Affinity Asset Advisors reports 8.4% beneficial stake

Affinity Asset Advisors, LLC and Michael Cho have reported an 8.4% beneficial stake in Lexeo Therapeutics (LXEO) through an amended Schedule 13G filing. This includes 6,674,913 shares of common stock, with 867,302 shares issuable upon warrant exercise, as of June 30, 2026. The reporting …

Maravai LifeSciences (MRVI) group reports 4.0M shares, 2.72% beneficial stake

A group including Hudson View Holdings LLC and JD Squared Holdings II LLC, along with individuals Stuart Feldman, Matthew Barkoff, and Joshua Wool, has reported a collective beneficial ownership of 4,009,250 shares, representing a 2.72% stake in Maravai LifeSciences Holdings, Inc. Class A common …

Verve Capital Limited (VOR) reports 6.3% stake in Vor Biopharma common stock

Verve Capital Limited has reported a 6.3% beneficial ownership stake in Vor Biopharma Inc. (VOR) common stock as of June 30, 2026. This ownership includes 3,410,892 shares, with Verve Capital holding sole voting and dispositive power. The filing, an amended SCHEDULE 13G/A, was signed …

Atrium Therapeutics, Inc. Q2 2026: Revenue $3M, EPS $(1.18) — 10-Q Summary

Atrium Therapeutics, Inc. reported its Q2 2026 results, with revenue declining to $3M from $3.85M in the prior year, and a diluted loss per share of $(1.18), worse than $(0.75) year-over-year. Despite the financial decline, the company highlighted an increase in collaboration revenue, clinical …

Form 8K Atrium Therapeutics Inc For: 13 August By Investing.com

This article from Investing.com is a brief announcement regarding an 8K filing by Atrium Therapeutics Inc. for August 13th. The content is very minimal, essentially serving as a headline to notify readers of the regulatory filing, without providing any further details about the filing …

Crinetics Pharmaceuticals (CRNX): Wellington reports 7.13M-share, 6.76% ownership

Wellington Management entities have reported beneficial ownership of 7,131,084 shares, or 6.76%, of Crinetics Pharmaceuticals (CRNX) common stock. The filing indicates shared voting power over 6,310,651 shares and shared dispositive power over all 7,131,084 shares, with economic interests belonging to advisory clients. No single …

Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Ensysce Biosciences announced its Q2 2026 financial results, highlighted by the acquisition of Cy Biopharma, Inc., which adds CY200 for Complex Regional Pain Syndrome (CRPS) to its pipeline. This acquisition, coupled with private placement financings, provides up to $77 million in new funding, extending …

Moleculin Biotech (NASDAQ: MBRX) advances AML trial but warns on cash

Moleculin Biotech (NASDAQ: MBRX) is progressing with its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed/refractory AML, showing promising preliminary efficacy and cardiac safety data. Despite these clinical advancements and a recent $9.3 million equity/warrant offering, the company reported a net loss of …

Edesa Biotech (EDSA) loss widens to $11.9M as R&D surges and cash tightens

Equillium, Inc. Q2 2026: Net loss $(4.7)M, EPS $(0.04) — 10-Q Summary

Equillium, Inc. reported a net loss of $(4.7)M, or $(0.04) diluted loss per share, for Q2 2026, an improvement compared to the previous year. The company's cash and cash equivalents increased to $57.2M, and it raised approximately $65M through private placements to fund operations …

Affinity Asset Advisors reports 4.1M Equillium (EQ) shares, a 6.5% stake

Affinity Asset Advisors, LLC and its managing member Michael Cho have reported beneficial ownership of 4,100,000 shares of Equillium Inc. (EQ) common stock, representing a 6.5% stake in the company. This ownership is held through Affinity Healthcare Fund, LP, with sole voting and dispositive …

Form 8K Equillium Inc For: 13 August By Investing.com

This article announces the filing of a Form 8K by Equillium Inc. for August 13. It provides the publication details and mentions that there are currently no comments on the filing. The company's stock symbol is EQ, and its price performance is noted.

Cadrenal Therapeutics reports Q2 2026 net loss of $3.3M; cash runway into Q1 2027

Cadrenal Therapeutics reported a net loss of $3.3 million for Q2 2026, an improvement from $3.7 million in Q2 2025. The company's cash and equivalents of approximately $4.2 million are expected to fund operations into Q1 2027. Additionally, Cadrenal launched a strategic partnering process …